Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, SLCO1B1 gene polymorphism frequency in Russian and Nanai populations

Introduction. The efficiency and safety of a drug therapy depends on the peculiarities of functioning of P450 cytochrome group and transporting proteins a lot. Materials and methods. We have studied the peculiarities of some P450 cytochrome polymorphisms’, SLCO1B1 transporting proteins’ and P-glycoproteins carriage of the healthy volunteers in Nanai ethnic group, living in Russia and compared them to the carriage of SNP in Russian population according to the literary data. Results. After performing the real-time polymerase chain reaction on the samples of 70 healthy volunteers from Nanai ethnic group for the CYP2C9*2 (C430T) polymorphism we have determined 70 CC-genotype carriers, for the CYP2C9*3 (А1075С) polymorphism – 62 AA-genotype carriers, AC-genotype – 8 carriers. For the CYP2C19*2 (G681A) polymorphism we have determined 39 GG-genotype carriers, GA-genotype – 28 carriers, for the CYP2C19*3 (G636A) polymorphism – 58 GG-genotype carriers, GA-genotype – 12 carriers, for the CYP2C19*17 (C806T) polymorphism – CC-genotype – 67 carriers, CT-genotype – 3 carriers. For the CYP2D6*4 (G1846A) polymorphism – GG-genotype – 68 carriers, GA-genotype – 2 carriers. For the ABCB1 (C3435T) polymorphism – CC-genotype – 19 carriers, CT-genotype – 39 carriers. For the SLCO1B1*5 (T521C) polymorphism – TT-genotype – 41 carrier, CT-genotype – 25 carriers. The distribution of the genotypes fitted the Hardy-Weinberg equilibrium for all the polymorphisms except the CYP2C9*2. There were also significant differences in allele frequencies for some polymorphisms between the Nanai’s and the Russians. Conclusions. In Nanai population there are polymorphisms, connected with the decrease of safety and efficiency of drug therapy. Studying the ethnic differences might influence the determination of the priority in the introduction of the pharmacogenetic test in clinical practice in different regions of Russia.

pharmacogenetics, ethnicity, cytochrome, Asians, Europeans, polymorphism, the SNP

1. Almazroo O.A., Miah M.K., Venkataramanan R. Drug Metabolism in the Liver. Clin Liver Dis. 2017; 21(1): 1–20.

2. Yasmina A., Deneer V.H., Maitland-van der Zee A.H. et al. Application of routine electronic health record databases for pharmacogenetic research. J Intern Med. 2014;275(6):590-604.

3. Caudle K.E., Klein T.E., Hoffman J.M. et al. Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process. Curr Drug Metab. 2014; 15(2): 209–217.

4. Fricke-Galindo I., Céspedes-Garro C., Rodrigues-Soares F. et al. Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. Pharmacogenomics J. 2016; 16(2): 113–123.

5. Hua Tang, Tom Quertermous, Beatriz Rodriguez, et al. Genetic Structure, Self-Identified Race/Ethnicity, and Confounding in Case-Control Association Studies. Am. J. Hum. Genet. 2005;76:268–275.

6. Caudle K.E., Rettie A.E., Whirl-Carrillo M. et al. Clinical Pharmacogenetics Implementation Consortium. Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharmacol Ther. 2014; 96(5): 542-548.

7. Hicks J.K., Bishop J.R., Sangkuhl K., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors. Clin Pharmacol Ther. 2015; 98(2): 127–134.

8. Karaĩniewicz-áada M., Danielak D., Rubiğ B. et al. Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites. J Clin Pharm Ther. 2015;40(2):226-231.

9. Ramsey L.B., Johnson S.G., Caudle K.E. et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014;96(4):423–428.

10. Vasilyev F.F., Danilova D.A., Kaimonov V.S. et al. Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population. Res Pharm Sci. 2016; 11(3): 259–264.

11. Sychev D.A., Shuev G.N., Chertovskih J.V. et al. The frequency of SLCO1B1*5 polymorphism genotypes among Russian and Sakha (Yakutia) patients with hypercholesterolemia. Pharmgenomics Pers Med. 2016; 9:59-63.

12. Чертовских Я.В., Шуев Г.Н., Попова Н.В. и др. Полиморфизм гена SLCO1B1, ассоциированный с развитием миопатии при приеме статинов, у пациентов с гиперлипидемией русских и якутов (саха). Молекулярная медицина. 2016; 1: 54–58.

13. Korytina G., Kochetova O., Akhmadishina L. et al. Polymorphisms of Cytochrome P450 Genes in Three Ethnic Groups from Russia. Balkan Med J. 2012; 29(3): 252–260.

14. Mustafina O.E., Tuktarova I.A., Karimov D.D. et al. CYP2D6, CYP3A5, and CYP3A4 gene polymorphism in Russian, Tatar and Bashkir populations. Genetika. 2015; 51(1): 109–119

15. Duzhak T., Mitrofanov D., Ostashevskii V. et al. Genetic polymorphisms of CYP2D6, CYP1A1, GSTM1 and p53 genes in a unique Siberian population of Tundra Nentsi. Pharmacogenetics. 2000; 10(6): 531–537.

16. Makeeva O., Stepanov V., Puzyrev V. et al. Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes. Pharmacogenomics. 2008; 9(7): 847–868.

17. Korshunova N., Katsuyama H., Demura M. et al. Posttraumatic stress disorders in the Nanai after pollution of the Amur River: ethnocultural analysis. Environ Health Prev Med. 2013; 18(6): 485–493.

18. Céspedes-Garro C., Fricke-Galindo I., Naranjo M.E. et al. Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes. Expert Opin Drug Metab Toxicol. 2015; 11(12): 1893–1905.

19. URL: https://www.pharmgkb.org/gene/PA126

20. Fricke-Galindo I., Céspedes-Garro C., Rodrigues-Soares F. et al. Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations. Pharmacogenomics J. 2016; 16(2): 113–123.

21. URL: https://www.pharmgkb.org/gene/PA124

22. Lerena A., Naranjo M.E., Rodrigues-Soares F. et al. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations. Expert Opin Drug Metab Toxicol. 2014; 10(11): 1569–1583

23. URL: https://www.pharmgkb.org/gene/PA128

24. Ameyaw M.M., Regateiro F., Li T. et al. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics. 2001; 11(3): 217–221.

25. Pasanen M.K., Neuvonen P.J., Niemi M. Global analysis of genetic variation in SLCO1B1. Pharmacogenomics. 2008 Jan; 9(1): 19–33.

26. URL: https://www.pharmgkb.org/gene/PA134865839

27. Gaikovitch E.A., Cascorbi I., Mrozikiewicz P.M. et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. Eur J Clan Pharmacol. 2003; 59(4): 303–312.

28. Gra O., Mityaeva O., Berdichevets I. et al. Microarray-based detection of CYP1A1, CYP2C9, CYP2C19, CYP2D6, GSTT1, GSTM1, MTHFR, MTRR, NQO1, NAT2, HLA-DQA1 and AB0 allele frequencies in native Russians. Genet Test Mol Biomarkers. 2010; 14(3): 329–342.

29. Sychev D.A., Denisenko N.P., Sizova Z.M. et al. The frequency of CYP2C19 genetic polymorphisms in Russian patients with peptic ulcers treated with proton pump inhibitors. Pharmgenomics Pers Med. 2015; 8: 111–114.